| Autor: |
Waterbury, L. David, Flach, Allan J. |
| Předmět: |
|
| Zdroj: |
Journal of Ocular Pharmacology & Therapeutics; Jun2006, Vol. 22 Issue 3, p155-159, 5p, 2 Graphs |
| Abstrakt: |
Purpose: The aim of this study was to compare the anti-inflammatory activities of ketorolac tromethamine 0.4% and 0.1%; diclofenac sodium 0.1%; and loteprednol etabonate 0.5% suspension in an animal model of ocular inflammation. Methods: An ocular inflammatory response was induced in New Zealand White rabbits by the intravenous (i.v.) administration of 10 µg/kg lipopolysaccharide (LPS). In study animals, 1 eye was treated topically with 50 µL of study medication (n = 8 animals per drug) and the other eye was treated topically with a 50- µL vehicle (buffered saline). In control animals (n = 8), both eyes were treated with vehicle. All animals were treated twice: 2 h and 1 h before LPS challenge. The breakdown of the blood-aqueous barrier in the anterior chamber was measured by fluorophotometry (FITC-dextran 30 mg/kg, i.v. given immediately after LPS challenge). Aqueous prostaglandin E2 (PGE2) levels were measured using an enzyme-linked immunosorbent assay (ELISA) immunoassay. Results: Ketorolac 0.4% resulted in a nearly complete inhibition of endotoxin-induced increases in FITC-dextran and PGE2 synthesis ( P < 0.001 vs. vehicle). Diclofenac 0.1% had much less of an effect on these parameters ( P < 0.01 vs. ketorolac 0.4%). Loteprednol 0.5% was no more effective than vehicle at inhibiting increases in FITC-dextran. Conclusions: Ketorolac has greater anti-inflammatory effects than diclofenac and loteprednol. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
